Hi Dr Tillett,
I was looking through the reports and noticed a significant increase in the expected cost of manufacturing and distribution. Are you able to provide an insight if this is due to increased requirement for clinical trials, or if this may be to increase supply for further NPP approvals (eg. Europe)? My understanding that last qrt expenses on manufacturing and distribution was adequate for Sheba Medical Centre and an increase must be for other purposes - happy to be corrected.
What is the shelf life of Bisantrene?
Cheers
Ann: Appendix 4C - quarterly, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.030(2.52%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $78.70K | 66.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 4561 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.19 | $1.22 | $1.16 | 11297 | ||
| Last updated 15.56pm 07/05/2024 ? | |||||
| RAC (ASX) Chart |